Figure 3.

Skin lesions suggestive of polymorphic erythema after acquiring SARS-CoV-2 infection during treatment with Pem/Pembro for metastatic lung adenocarcinoma. CBP (AUC 5)/Pem 500 mg/m²/day/Pembro 200 mg every 21 days for 4 cycles then Pem/Pembro for 31 cycles. (C-red) contact with a patient infected with COVID-19; (A) beginning of the cutaneous manifestations; (B) remarkable extension of skin lesions, elevation of biomarkers and start of HCQ; (C) pathology with interface dermatitis; (D) normal chest radiograph; (E) progressive regression of skin lesions and appearance of oral ulcers, which became the basis for starting methylprednisolone. CBP, carboplatin; COVID-19, coronavirus 2019; CT, computed tomography; HCQ, Hydroxychloroquine; LUAD, lung adenocarcinoma; Pem, pemetrexed; Pembro, pembrolizumab; PR, partial response; RT-PCR, reverse transcriptase–polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome–coronavirus-2.